Funding for this research was provided by:
Agency for Healthcare Research and Quality (R18 HS023757, K01HS025486)
National Center for Advancing Translational Sciences (2 UL1 TR000445-06)
U.S. Department of Veterans Affairs (12-168)
National Center for Research Resources (UL1 RR024975-01)
Text and Data Mining valid from 2019-09-11
Received: 27 November 2018
Accepted: 28 August 2019
First Online: 11 September 2019
Ethics approval and consent to participate
: This operational improvement work was reviewed and granted approval at each local site. The Partners Institutional Review Board (IRB) served as the principal IRB of record. Each site obtained either waiver or approval from their respective IRB for collection of data pertinent to the study and approval to share deidentified data with the research team. The site IRBs include: Griffin Hospital, University of Utah, Cooper University Hospital, University of California San Diego, San Joaquin Community Hospital, Johns Hopkins Medicine, RWJ University Hospital Somerset, Yale New Haven Hospital, Niagara Health System, University of California Davis Medical Center, Oregon Health and Science University, McLeod Regional Medical Center, Denver Health Medical Center, University of Florida, Mission Hospital, Doylestown Hospital, VA Boston Healthcare System, University of Kentucky Chandler Hospital.
: Not applicable.
: Dr. Schnipper has received funding from Mallinckrodt Pharmaceuticals for an investigated-initiated study of opioid-related adverse drug events and from Portola Pharmaceuticals for an investigator-initiated study of inpatients who decline subcutaneous venous thromboembolism prophylaxis. No other authors have conflicts of interest or financial disclosures.